- Home
- IMUX vs ACHV Comparison
IMUX vs ACHV Comparison
Compare IMUX & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- ACHV
- Stock Information
- Founded
- IMUX 2016
- ACHV N/A
- Country
- IMUX United States
- ACHV Canada
- Employees
- IMUX N/A
- ACHV N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IMUX Health Care
- ACHV Health Care
- Exchange
- IMUX Nasdaq
- ACHV Nasdaq
- Market Cap
- IMUX 102.2M
- ACHV 92.6M
- IPO Year
- IMUX N/A
- ACHV N/A
- Fundamental
- Price
- IMUX $1.09
- ACHV $2.70
- Analyst Decision
- IMUX Strong Buy
- ACHV Strong Buy
- Analyst Count
- IMUX 7
- ACHV 4
- Target Price
- IMUX $12.67
- ACHV $15.75
- AVG Volume (30 Days)
- IMUX 555.7K
- ACHV 162.2K
- Earning Date
- IMUX 05-07-2025
- ACHV 03-11-2025
- Dividend Yield
- IMUX N/A
- ACHV N/A
- EPS Growth
- IMUX N/A
- ACHV N/A
- EPS
- IMUX N/A
- ACHV N/A
- Revenue
- IMUX N/A
- ACHV N/A
- Revenue This Year
- IMUX N/A
- ACHV N/A
- Revenue Next Year
- IMUX N/A
- ACHV N/A
- P/E Ratio
- IMUX N/A
- ACHV N/A
- Revenue Growth
- IMUX N/A
- ACHV N/A
- 52 Week Low
- IMUX $0.92
- ACHV $2.51
- 52 Week High
- IMUX $2.11
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- IMUX 46.81
- ACHV 41.28
- Support Level
- IMUX $1.18
- ACHV $2.70
- Resistance Level
- IMUX $1.28
- ACHV $2.99
- Average True Range (ATR)
- IMUX 0.07
- ACHV 0.20
- MACD
- IMUX -0.00
- ACHV 0.01
- Stochastic Oscillator
- IMUX 6.00
- ACHV 34.55
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.